NIB biotec on stage at the Longevity World Forum 2026

NIB biotec is among the eight startups selected by the scientific committee of the Longevity World Forum (LWF) 2026 as one of the projects with the greatest potential to extend life expectancy and promote truly healthy aging.

The appointment is from 18 to 20 February 2026 at La Nave, Madrid, during one of the most authoritative international conferences dedicated to longevity, preventive health and the technologies that are redefining the future of medicine (official page).

An event that unites science, technology and the future of health

The Longevity World Forum is recognized as one of the leading global summits on healthy aging. It brings together world-class researchers, clinicians, biotech companies, investors, and innovation professionals to explore the latest advances in fields such as geroscience, biomarkers, regenerative medicine, advanced prevention, and AI applied to health.

The 2026 edition features a rich program, divided into three main areas: science, trends, and entrepreneurship, with international keynote speakers and a strong focus on emerging technologies, from biomarkers of aging to personalized medicine based on genetics, metabolomics, and artificial intelligence.

In this highly selective context, the LWF has identified eight startups with solutions considered particularly promising in the field of prevention, early diagnosis and tissue regeneration, using technologies such as AI, genetics, microbiota, 3D bioprinting and biomarkers (link).

The official selection: NIB biotec among the eight most promising projects

Among the eight finalist startups, NIB biotec was selected thanks to our non-invasive urinary test for the advanced diagnosis of prostate cancer, based on proprietary molecular biomarkers.

The other finalist startups address topics such as neuroscience-based digital longevity, predictive genetics, advanced imaging for atherosclerosis, microbiota metagenomics, cellular sensors, and 3D solutions for regeneration and orthopedics. This places our project in a world of elite innovation, demonstrating the international interest in truly transformative preventive and diagnostic solutions.

What NIB biotec will present at the Longevity World Forum 2026

During the pitch to investors, researchers, and stakeholders in the longevity sector, we will present our technology, which enables the early identification of patients at risk of prostate cancer, improving the diagnostic process and redefining access to active surveillance programs and personalized treatments.

Early diagnosis of prostate cancer is one of the most effective interventions for increasing not only life expectancy but, above all, the quality of life of men over 50, directly contributing to the key objectives of the Longevity World Forum.

Why our solution makes the difference

The selection at LWF recognizes NIB Biotec's potential to:

• respond to an unmet clinical need, such as the accurate and non-invasive diagnosis of prostate cancer;
• reduce the use of unnecessary biopsies, reducing costs, times and impact on the patient;
• accelerate the clinical decision-making process, thanks to an objective and measurable biomarker;
• promote accessible precision medicine, based on rapid tests that can be easily integrated into the clinical pathway.

As LWF Director Francisco Larrey emphasized, the competition's goal is to highlight early-stage projects with high potential, capable of making a real impact on global health.

A step forward on our journey

Being selected as a finalist represents significant recognition of our team's work and the scientific validity of our research. It is also an important opportunity to present our project to an international audience of experts, investors, and strategic partners, consolidating our role among the most innovative players in the European longevity and cancer prevention landscape.